Search results

In this study, a different approach is introduced to generate the kinetic sub-model for the modeling of solid-state pyrolysis reactions based on the thermogravimetric (TG) experimental data over a specified range of heating rates. Gene Expression Programming (GEP) is used to produce a correlation for the single-step global reaction rate as a function of determining kinetic variables, namely conversion, temperature, and heating rate.

For a case study on the coal pyrolysis, a coefficient of determination (R²) of 0.99 was obtained using the generated model according to the experimental benchmark data. Comparison of the model results with the experimental data proves the applicability, reliability, and convenience of GEP as a powerful tool for modeling purposes in the solid-state pyrolysis reactions.

The resulting kinetic sub-model takes advantage of particular characteristics, to be highly efficient, simple, accurate, and computationally attractive, which facilitates the CFD simulation of real pyrolizers under isothermal and non-isothermal conditions.

It should be emphasized that the above-mentioned manuscript is not under evaluation in any journals and submitted exclusively for consideration for possible publication in this journal. The generated kinetic model is in the final form of an algebraic correlation which, in comparison to the conventional kinetic models, suggests several advantages: to be relatively simpler, more accurate, and numerically efficient. These characteristics make the proposed model computationally attractive when used as a sub-model in CFD applications to simulate real pyrolizers under complex heating conditions.

For years, traditional techniques have been used for diabetes treatment. There are two major types of insulin: insulin analogs and regular insulin. Insulin analogs are similar to regular insulin and lead to changes in pharmacokinetic and pharmacodynamic properties. The purpose of the present research was to determine the cost-effectiveness of insulin analogs versus regular insulin for diabetes control in Yazd Diabetes Center in 2017.

In this descriptive–analytical research, the cost-effectiveness index was used to compare insulin analogs and regular insulin (pen/vial) for treatment of diabetes. Data were analyzed in the TreeAge Software and a decision tree was constructed. A 10% discount rate was used for ICER sensitivity analysis. Cost-effectiveness was examined from a provider's perspective.

QALY was calculated to be 0.2 for diabetic patients using insulin analogs and 0.05 for those using regular insulin. The average cost was $3.228 for analog users and $1.826 for regular insulin users. An ICER of $0.093506/QALY was obtained. The present findings suggest that insulin analogs are more cost-effective than regular insulin.

This study was conducted using a cost-effectiveness analysis to evaluate insulin analogs versus regular insulin in controlling diabetes. The results of study are helpful to the government to allocate more resources to apply the cost-effective method of the treatment and to protect patients with diabetes from the high cost of treatment.